Jack Khattar Biography and Net Worth

Director of scPharmaceuticals

Jack A. Khattar is the founder of Supernus Pharmaceuticals (NASDAQ:SUPN) and has served as president and chief executive officer and director since 2005. From 1999 to 2005, Mr. Khattar served in various positions, including board member, president and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. Prior to that, Mr. Khattar served as an executive officer and the chairman of the management committee at CIMA, a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex, and Kodak in various locations, including the United States, Europe and the Middle East. He served as a director of Rockville Economic Development Inc. from 2003 until 2013. He currently serves on the board of directors of Prevacus, Inc., a privately-held pharmaceutical company. Mr. Khattar earned his degrees in Marketing, with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.

What is Jack A. Khattar's net worth?: The estimated net worth of Jack A. Khattar is at least $3.14 million as of November 7th, 2024. Mr. Khattar owns 926,172 shares of scPharmaceuticals stock worth more than $3,139,723 as of December 22nd. This net worth evaluation does not reflect any other assets that Mr. Khattar may own. Learn More about Jack A. Khattar's net worth.
How do I contact Jack A. Khattar?: The corporate mailing address for Mr. Khattar and other scPharmaceuticals executives is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. scPharmaceuticals can also be reached via phone at (617) 517-0730 and via email at [email protected]. Learn More on Jack A. Khattar's contact information.
Has Jack A. Khattar been buying or selling shares of scPharmaceuticals?: Jack A. Khattar has not been actively trading shares of scPharmaceuticals during the last quarter. Most recently, on Friday, December 3rd, Jack A. Khattar bought 5,000 shares of scPharmaceuticals stock. The stock was acquired at an average cost of $3.91 per share, with a total value of $19,550.00. Learn More on Jack A. Khattar's trading history.
Who are scPharmaceuticals' active insiders?: scPharmaceuticals' insider roster includes Jack Khattar (Director), and John Tucker (CEO). Learn More on scPharmaceuticals' active insiders.

Jack A. Khattar Insider Trading History at scPharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/3/2021	Buy	5,000	$3.91	$19,550.00

Jack A. Khattar Buying and Selling Activity at scPharmaceuticals

scPharmaceuticals Company Overview

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Today's Range

Now: $3.39

$3.24

$3.45

50 Day Range

MA: $3.81

$3.14

$4.53

2 Week Range

Now: $3.39

$3.08

$6.71

Volume

2,870,967 shs

Average Volume

294,288 shs

Market Capitalization

$169.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.